Cormorant Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-1,175,000
Closed -$25.4M 62
2023
Q4
$25.4M Buy
+1,175,000
New +$18.1M 1.21% 24
2017
Q2
Sell
-240,403
Closed -$3.3M 77
2017
Q1
$3.3M Hold
240,403
0.48% 48
2016
Q4
$1.72M Hold
240,403
0.23% 65
2016
Q3
$3.65M Buy
240,403
+25,984
+12% +$342K 0.4% 59
2016
Q2
$2.11M Hold
214,419
0.3% 58
2016
Q1
$2.86M Buy
+214,419
New +$2.7M 0.43% 54

Other funds holding SNDX

Cormorant Asset Management's SNDX Position: Q1 2024 in Review

Cormorant Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2024, closing a stake of 1,175,000 shares — an estimated $25.4M sold.

Cormorant Asset Management first reported a position in SNDX in Q1 2016 and held it in 6 quarters. The position peaked at $25.4M in Q4 2023. 189 funds tracked by Wall St. Rank hold SNDX as of Q1 2024.

  • Cormorant Asset Management reported no remaining Syndax Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 1,175,000 Syndax Pharmaceuticals shares in Q1 2024, an estimated $25.4M.
  • Cormorant Asset Management first reported a position in Syndax Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • Cormorant Asset Management's Syndax Pharmaceuticals position peaked at $25.4M in Q4 2023.
  • 189 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2024.

Based on Cormorant Asset Management's 13F filing for Q1 2024, filed 15 May 2024.